Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling) |  |
|
|
| IL6-H4218 | Human | ActiveMax® Human IL-6 Protein, Tag Free |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Pomalidomide | CC-4047; CDC-394; IMID-4047; IMiD-1 | Approved | Celgene | POMALYST | fda | Multiple myeloma (MM) | CELGENE | 2013-02-08 | Multiple myeloma (MM) | Details |
| Luminol sodium | MP-1032,MP1032 | Approved | Metrio, Selvim | Psoriasis, Immunological disorders | Details | |||||
| Lenalidomide | CDC-501; CC-5013; CDC-5013; ENMD-0997; IMID-5013; IMiD-3 | Approved | Celgene, BeiGene | REVLIMID | fda | Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM) | CELGENE | 2005-12-27 | Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM), Peripheral T cell lymphoma (PTCL) | Details |
| Siltuximab | CNTO-328; cCLB-8,CNTO328,cCLB8 | Approved | Janssen, EUSA Pharma | SYLVANT | fda | Multicentric Castleman's Disease (MCD) | JANSSEN BIOTECH | 2014-04-23 | Multicentric Castleman's Disease (MCD) | Details |
| Thalidomide | NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 | Approved | Celgene | THALOMID | fda | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | CELGENE | 1998-07-16 | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Atiprimod dihydrochloride | SK&F-106615-A2 | Phase Ⅱ | Genzyme, GlaxoSmithKline, Callisto | Osteoarthritis (OA), Solid tumours, Multiple myeloma (MM), Rheumatoid arthritis (RA) | Details |
| BLX-1002 | BLX-1002 | Phase Ⅱ | Orchid | Type 2 diabetes | Details |
| Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | BLA Filing | Prometic Life Sciences | Bladder cancer | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase Ⅲ | Alder Biopharmaceuticals | Psoriatic arthritis, Inflammation, Rheumatoid arthritis (RA), Rejection of renal transplantation | Details |
| APX-007 (Apexigen/Epitomics) | APX-007 | Preclinical | Epitomics, Apexigen | Inflammation | Details |
| MEDI-5117 | MEDI-5117; WBP-216,WBP216; MEDI5117 | Phase Ⅰ | WuXi AppTec, MedImmune | Rheumatoid arthritis (RA) | Details |
| QR-449 | QR-440; QR-443; QR-449 | Phase Ⅰ | ProPhase Labs | Cachexia, Metabolic disorders, Pain | Details |
| EBI-031 | EBI-031,EBI031 | Phase Ⅰ | Sesen Bio, Roche | Uveitis, Diabetic macular edema | Details |
| Gerilimzumab | ARGX-109; GB-224; RYI-008 | Phase Ⅱ | arGEN-X, Bird Rock Bio, Genor Biopharma | Rheumatoid arthritis (RA) | Details |
| Ziltivekimab | COR-001,COR 001 | Phase Ⅱ | AstraZeneca, Corvidia Therapeutics | Cardiovascular disorders, Chronic kidney disease | Details |
| Anti-IL-6 mAb (Vaccinex) | OPR-003; VX-30; mAb-1339 | Phase Ⅰ | Vaccinex, EUSA Pharma | hematological malignancies, Rheumatoid arthritis (RA) | Details |
| Elsilimomab (Orphan Pharma international) | Phase Ⅱ | AOP Orphan Pharmaceuticals, Orphan Pharma international | Multiple myeloma (MM), Lymphoma | Details | |
| FM-101 (Femta Pharmaceuticals) | FM-101 | Preclinical | Femta Pharmaceutical | Multiple myeloma (MM), Rheumatoid arthritis (RA), Crohn's disease | Details |
| Sirukumab | BA-003;CNTO-136,BA003,CNTO136 | BLA Filing | GlaxoSmithKline, Janssen | Rheumatoid arthritis (RA) | Details |
| Y-25510 | Y-25510 | Phase Ⅰ | Mitsubishi Tanabe Pharma | Leucopenia, Thrombocytopenia | Details |
| Interleukin-6 receptor (Tosoh) | CD-126 | Preclinical | Tosoh | Stem cell mobilization | Details |
| FB-704A | FB-704; FB-704A | Phase Ⅰ | Fountain BioPharma | Rheumatoid arthritis (RA) | Details |
| YS-IL6 | YS-IL6; YSIL-6; YSIL6-O-RA; YSIL6-T-PS | Phase Ⅱ | Y's Therapeutics | Rheumatoid arthritis (RA) | Details |
| TA-383 | TA-383 | Phase Ⅱ | Mitsubishi Tanabe Pharma | Rheumatoid arthritis (RA) | Details |
| KOB-03 | KOB-03 | Phase Ⅱ | Dong Wha Pharmaceuticals | Allergic rhinitis (AR) | Details |
| ME-3738 | ME-3738 | Phase Ⅱ | Meiji Seika Pharma | HCV infection | Details |
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase Ⅱ | Biocad | Autoimmune diseases | Details | |
| HL-2351 | HL-2351; GX-P4; rhIL-1Ra-hyFc | Phase Ⅱ | Genexine, Handok Inc | Rheumatic disorders, Cryopyrin-Associated Periodic Syndromes (CAPS) | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase Ⅰ | Mycenax Biotech | Rheumatoid arthritis (RA) | Details | |
| Olokizumab | Anti-IL6-UCB; CDP-6038 | Phase Ⅲ | UCB, R-Pharm | Rheumatoid arthritis (RA) | Details |
| AMG-220 | C-326; AMG-220 | Phase Ⅰ | Amgen | Crohn's disease | Details |
| Cis-urocanic acid | UCA-001; UCA-002; Cis-UCA | Phase Ⅱ | Herantis Pharma | Atopic dermatitis, Dry eye disease | Details |
| PF-04236921 | PF-04236921; PF-4236921 | Phase Ⅱ | Pfizer | Crohn's disease | Details |
| Wogonin | Phase Ⅰ | Daewoong, China Pharmaceutical University, Hefei Cosource Medicine Technology, Buchang Pharma | Gastric cancer, Leukemia, Liver cancer | Details | |
| PXL-01 | PXL-01 | Phase Ⅲ | ProMore Pharma, Technomark Life Sciences, PharmaResearch Products | Post-surgical adhesions | Details |
This web search service is supported by Google Inc.
A-Z